Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

OM336

Bispecific antibody · Immune activation, directed at B-cell maturation antigen (TNFRSF17) and CD3 (CD3E) · developed by Lakefront Biotherapeutics West LLC

Phase 1 Most advanced trial
LKFT Developer
1 Registered trials

What is OM336?

OM336 is an engineered bispecific antibody that binds BCMA and CD3. It is being studied in Sjogren's disease and idiopathic inflammatory myopathy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Bispecific antibody
Targets
B-cell maturation antigen (TNFRSF17), CD3 (CD3E)
Mechanism
Immune activation, directed at B-cell maturation antigen (TNFRSF17) and CD3 (CD3E)
Therapy area
Musculoskeletal
Developer
Lakefront Biotherapeutics West LLC (LKFT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07229144 Phase 1 Sjogrens Disease Recruiting LKFT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Idiopathic Inflammatory Myopathy (IIM)Sjogrens Disease

Other drugs acting on TNFRSF17 / CD3E

More from Lakefront Biotherapeutics West LLC

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LKFT page.

Follow LKFT, the company behind OM336

See LKFT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LKFT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.